Nexalin Technology (NXL) Other Accumulated Expenses (2021)
Nexalin Technology's (NXL) quarterly Other Accumulated Expenses came in at $42843.0 in Q4 2021.
Nexalin Technology (NXL) Other Accumulated Expenses (2021) Analysis & Trends
Nexalin Technology's Other Accumulated Expenses history runs 1 years deep, the most recent figure standing at $42843.0 for Q4 2021.
- On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $42843.0 in Q4 2021; TTM through Dec 2021 was $42843.0, a N/A change from a year earlier, with the FY2021 full-year figure at $42843.0, changed N/A from the prior year.
- Other Accumulated Expenses held at $42843.0 in Q4 2021 per NXL's latest filing.
- Across five years, Other Accumulated Expenses topped out at $42843.0 in Q4 2021 and bottomed at $42843.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn |
| 10 | Nexalin Technology | 9.07 Mn | 6.36 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 42,843.00 |